Tag: Xiidra

In 2023, eye health company Bausch + Lomb acquired Xiidra from Novartis in a deal worth up to $2.5 billion. For patients wondering, “Is Xiidra being discontinued?”, this change in ownership confirms the medication's continued availability and future in the dry eye treatment market.

Chronic dry eye disease affects millions of adults, causing discomfort and irritation. The answer to the question, **'Can you buy XIIDRA over-the-counter?'** is no, as this targeted anti-inflammatory eye drop is only available with a doctor's prescription.

An estimated 16 to 50 million Americans suffer from dry eye disease, a common reason for visiting an eye doctor [1.10.1, 1.10.3]. For those managing this condition, a key question is: **Is there a replacement for Restasis?** The answer is yes, with multiple options available.

While most clinical studies for Xiidra did not identify dizziness as a common side effect, official patient information acknowledges that it may be a possible side effect in certain individuals. User reports have also linked the medication to dizziness, and severe dizziness can be a rare but serious symptom of an allergic reaction. It is important to understand the context and severity of this potential adverse event.

An estimated 16 million people in the U.S. are diagnosed with dry eye disease. Deciding what is the best prescription drug for dry eyes is not a one-size-fits-all answer, as the optimal treatment depends heavily on the underlying cause and severity of your condition. This guide explores various FDA-approved options, helping you understand their differences and potential benefits.

According to clinical studies, patients using Xiidra showed statistically significant improvements in both the signs and symptoms of dry eye. So, does Xiidra produce more tears? The answer is yes, but not by simply adding them; rather, it works by addressing the root cause of inflammation that impairs the eye's natural tear-producing ability.

Sjögren's syndrome is a chronic autoimmune disease affecting the body's moisture-producing glands. While not officially FDA-approved for Sjögren's itself, the question of 'Does Xiidra work for Sjögren's?' is critical for patients experiencing severe dry eye, a primary symptom of the condition.

As of September 2025, there is no therapeutically equivalent generic for Xiidra ophthalmic solution available in the United States. This means that the brand-name version, containing the active ingredient lifitegrast, is the only product currently on the market for this specific formulation.

In four clinical studies, Xiidra demonstrated a significant improvement in the signs and symptoms of dry eye disease, with some patients feeling relief in as little as two weeks [1.3.3, 1.3.4]. Deciding *Is Xiidra worth it?* involves weighing this clinical effectiveness against its high cost and potential side effects.

Affecting approximately 20 million people in the United States, Dry Eye Disease is a common and often chronic condition [1.11.1]. For those managing it with prescription drops, the question arises: is it okay to switch from Xiidra to Restasis? The answer is yes, but it requires a conversation with your doctor [1.2.3].